H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Sol-Gel Technologies Ltd (SLGL) today and set a price target of $23. The company’s shares closed on Friday at $10.19.
Selvaraju wrote:
“We have valued Sol-Gel based on a discounted cash flow (DCF) analysis. This yields a value of $205M for TWIN, assuming a 70% probability of approval, and a $190M valuation for Epsolay, assuming a 90% probability of approval. Sol-Gel’s partnered generic products contribute an aggregate of $75M. The total represents $470M, or a price per share of $23.00, assuming roughly 20.4M fully-diluted shares outstanding as of end-1Q20.”
According to TipRanks.com, Selvaraju has currently no stars on a ranking scale of 0-5 stars, with an average return of -5.1% and a 29.9% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Currently, the analyst consensus on Sol-Gel Technologies Ltd is a Moderate Buy with an average price target of $21.
See today’s analyst top recommended stocks >>
Based on Sol-Gel Technologies Ltd’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $5.73 million. In comparison, last year the company had a GAAP net loss of $6.91 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sol-Gel Technologies Ltd. is a clinical-stage dermatology company, which focuses on identifying, developing and commercializing topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel.
